Melanotan-1 (afamelanotide) is a synthetic analog of alpha-MSH that drives eumelanin production through the MC1 receptor. Because pigmentation builds biologically rather than instantly, the timeline is measured in days to weeks — clinical data tracks melanin density rising over the first two weeks before it plateaus, and community-reported tanning protocols follow a similar loading-then-maintenance arc.
This timeline draws on two evidence streams that are kept separate throughout: controlled clinical studies that measured melanin density with instruments, and self-reported community tanning timelines. The clinical data anchors the biology; community reports describe the cosmetic experience. They are not the same thing.
Research-context information only. Melanotan-1 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
Pigmentation is not a switch. MC1R activation upregulates tyrosinase and other melanogenic enzymes, and new eumelanin accumulates in melanocytes over days. The clearest human timing data comes from a controlled study in which five solar urticaria patients received a single 16 mg afamelanotide implant in winter: mean melanin density increased by day 7, peaked around day 15, and remained elevated at day 60 (Haylett et al., 2011).
That day-7-to-day-15 curve is the backbone of every phase below. Community-reported injection protocols compress or stretch it depending on dose frequency and UV exposure, but the underlying biology — a roughly two-week ramp before a plateau — is consistent across the clinical literature.
Week 1: Little Visible Change
What clinical data documents: In the controlled implant study, melanin density had begun increasing by day 7 but had not yet peaked (Haylett et al., 2011). The early week is biochemical priming — melanogenic machinery is upregulating, but visible color change lags the molecular signal.
What community sources describe: Self-reported community timelines commonly describe minimal visible tanning in the first 5-7 days. The most consistent community feedback is that the earliest noticeable sign is not skin color but transient side effects on injection days — brief facial flushing or mild nausea — rather than a tan.
What clinical data does not support: No clinical study describes meaningful cosmetic darkening within the first few days. Community reports of an overnight tan are not consistent with the documented melanin-density curve, which rises gradually.
What clinical data documents: This is the window where instrument-measured melanin climbs most steeply. In the implant study, density peaked around day 15 (Haylett et al., 2011). In the injection study, three 10-day cycles of 0.16 mg/kg over three months produced significant melanin-density increases by reflectance spectroscopy, with subjects who had the lowest baseline melanin showing the largest relative gains (Barnetson et al., 2006).
What community sources describe: This is the phase community sources label "loading." Users in community sources commonly describe the first visible darkening appearing somewhere in weeks 2-3, typically reading first on the face, shoulders, and other UV-exposed areas. Community-reported protocols describe pairing injections with short, gradually increasing UV sessions during this window, consistent with melanotan-1's UV-dependent mechanism.
What clinical data does not support: The clinical literature describes melanin gains, not a uniform deep tan. The fairest subjects saw the largest relative increase (Barnetson et al., 2006), but a fair starting point still means a modest absolute color at this stage. Community reports of dramatic full-body color by week 2 are at the high end of the distribution, not the norm.
Months 1-2: Plateau and Maintenance
What clinical data documents: After the day-15 peak, melanin density in the implant study remained elevated through day 60 rather than continuing to climb (Haylett et al., 2011). The biology favors holding a plateau, not endless deepening.
What community sources describe: Self-reported community timelines describe transitioning from loading to a maintenance phase around this point — the same or reduced injection frequency to hold the tan rather than build it. The most consistent community feedback is that maintenance requires far less peptide and UV than the loading phase to sustain color.
Documented safety note (not instruction): Across the clinical and community literature, darkening of moles and freckles is a documented effect of increased melanogenesis. Dermatology guidance on afamelanotide notes that pigmented lesions can darken, which can complicate skin-cancer surveillance (Minder et al., 2013). This is reported as a monitoring consideration documented in the literature, not as a directive.
Months 3-6: Long-Term Pattern
What clinical data documents: The longest human dataset is the long-term observational study of 115 EPP patients treated with afamelanotide implants over a period of up to 8 years, which reported sustained clinical benefit and good tolerability under routine long-term use (Biolcati et al., 2015). That study measured photoprotection and quality of life in a clinical population, not cosmetic tanning, so it speaks to long-term tolerability rather than to how dark recreational users get.
What community sources describe: Self-reported community timelines describe color fading over weeks once injections and UV stop, as pigmented skin cells turn over — consistent with melanin being a renewable, not permanent, response. Community-reported seasonal protocols commonly cycle (8 weeks on, 8 weeks off, per the melanotan-1 dosing guide), sometimes citing receptor desensitization as the rationale. Notably, the clinical evidence does not support a desensitization requirement: the Biolcati et al. dataset documents afamelanotide dosed repeatedly over up to 8 years with sustained efficacy and no reported loss of response. For ongoing photoprotection in light-sensitive use, continuous or seasonal maintenance dosing — not a desensitization-driven off-cycle — is the pattern the clinical literature actually documents.
What clinical data does not support: No published study describes a permanent tan from melanotan-1. The documented pattern is build, plateau, and fade — pigmentation tracks ongoing MC1R stimulation and UV input.
Bac Water Made for Peptides50% off
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
Response speed and depth vary widely. The variables documented across clinical studies and community sources:
Skin type (Fitzpatrick). The clinical melanin-density study found the largest relative gains in the fairest-skinned subjects — those with the least baseline melanin (Barnetson et al., 2006). In absolute terms, darker baseline phototypes start with more pigment and may perceive less dramatic change. Community sources commonly describe fair (type I-II) users seeing slower but proportionally larger shifts than already-tan users.
UV exposure. Melanotan-1 amplifies the UV response rather than replacing it. Clinical melanin assessments were paired with controlled light exposure, and community-reported protocols consistently pair injections with brief, gradual UV. Community sources describe minimal tanning when UV is omitted entirely — the defining difference from melanotan-2.
Dose. The clinical timing data comes from a 16 mg implant and 0.16 mg/kg injection cycles (Haylett et al., 2011; Barnetson et al., 2006). Community-reported recreational doses are far lower than the clinical implant; self-reported community timelines describe lower doses producing slower onset and a lighter plateau.
Consistency. Self-reported community timelines describe missed injections and inconsistent UV stretching out the loading phase. The clinical curve assumes steady exposure; gaps flatten it.
When to Adjust
Signals documented across clinical and community sources, framed descriptively rather than as instructions:
Signs the response is on track (per community sources): first visible darkening on UV-exposed areas somewhere in weeks 2-3, deepening through week 4, then a plateau — the cosmetic mirror of the day-15 clinical peak (Haylett et al., 2011).
What community sources describe when little changes: the most consistent community feedback for slow responders points to insufficient or omitted UV exposure, very low dose, or a darker baseline phototype that masks the relative gain. Community-reported protocols describe revisiting UV timing and consistency before changing dose.
Documented monitoring consideration: because new or darkening pigmented lesions are a documented effect (Minder et al., 2013), dermatology literature describes baseline and periodic skin checks for those on melanocortin agonists. This is reported as a documented practice, not advice — a licensed physician can advise on individual circumstances.
Frequently Asked Questions
How long did pigmentation changes take in clinical studies?
In a controlled study of solar urticaria patients given a single 16 mg afamelanotide implant, mean melanin density increased by day 7, peaked around day 15, and remained elevated at day 60 (Haylett et al., 2011). A separate Phase II study using 0.16 mg/kg subcutaneous injections across three 10-day cycles over 3 months reported significant melanin density increases by reflectance spectroscopy, with the largest gains in the fairest-skinned subjects (Barnetson et al., 2006).
Does melanotan-1 darken skin without UV exposure?
Published research and community sources both describe melanotan-1 as primarily amplifying the skin's response to UV rather than darkening skin on its own. Trial subjects in melanin-density studies were assessed with controlled light exposure, and community-reported tanning timelines consistently pair injections with brief UV from sun or beds.
What does the loading phase versus maintenance phase look like?
Community-reported protocols describe a loading phase of roughly 2-4 weeks to build baseline melanin, followed by a maintenance phase at the same or reduced frequency. This mirrors the clinical pigmentation curve, where melanin density climbed over the first 2 weeks before plateauing (Haylett et al., 2011).
What if no tanning is visible after the first couple of weeks?
Community sources describe response speed varying widely by Fitzpatrick skin type, baseline melanin, UV exposure, and dose consistency. The clinical literature notes the largest melanin gains occurred in the fairest subjects, but the absolute darkening was gradual rather than immediate (Barnetson et al., 2006). Community reports of seeing little change in the first 1-2 weeks are common; a licensed physician can advise on individual circumstances.
How does the melanotan-1 timeline compare to melanotan-2?
Community sources commonly describe melanotan-1 as producing a slower, more UV-dependent tan than melanotan-2, which is a multi-receptor agonist. The melanotan-1 vs melanotan-2 comparison covers the receptor and effect differences in detail.
Research Supplies for Melanotan I
Hand-picked storage, injection, and recovery supplies paired with Melanotan I protocols.
Haylett AK, et al. "Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-alpha-MSH." Br J Dermatol. 2011;164(2):407-414. PubMed
Barnetson RS, et al. "[Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers." J Invest Dermatol. 2006;126(8):1869-1878. PubMed
Biolcati G, et al. "Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria." Br J Dermatol. 2015;172(6):1601-1612. PubMed
Minder EI, et al. "A review and update on melanocyte stimulating hormone therapy: afamelanotide." J Recept Signal Transduct Res. 2013;33(5):261-266. PubMed
For educational and research purposes only. This is not medical advice. Research-peptide and compounded forms of afamelanotide are not FDA-approved for any indication.
